Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Nausea and Vomiting, Nausea, Vomiting
Interventions
Fosaprepitant for Injection, Metoclopramide Injection
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Terminated Phase 2 Interventional Results available

Bupivacaine for Benign Headache in the ED

NCT01785459
Conditions
Benign Headache
Interventions
0.5% bupivacaine, Standard Care
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroimmune Effects of Opioid Administration

NCT03801629
Conditions
Drug Effect
Interventions
High Morphine Dose, Low Morphine Dose
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Migraine
Interventions
metoclopramide, Dexamethasone, methylprednisolone acetate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
The Bronx, New York
Conditions
Safety, and Tolerability
Interventions
DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg
Combination Product · Drug
Lead sponsor
Aspeya Switzerland SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

NCT05967442
Conditions
Migraine, Headache
Interventions
Magnesium Sulfate, Metoclopramide 10mg, Prochlorperazine (Compazine) Injection
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Oak Lawn, Illinois
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Droperidol Versus Metoclopramide + Diphenhydramine for the Treatment of Primary Headaches

NCT01406860
Conditions
Primary Headaches (Includes Migraines, Tension, Cluster Headaches)
Interventions
Droperidol, Metoclopramide + diphenhydramine
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Phase 2 Interventional Results available

Metoclopramide Versus Placebo for GJ Placement

NCT03331965
Conditions
Radiation Exposure, Enteral Nutrition
Interventions
Metoclopramide 5 MG/ML Injectable Solution, Saline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Critical Illness, Enteral Nutrition, Enteral Feeding Intolerance
Interventions
TAK-954, Metoclopramide, Normal Saline
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
14
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Peoria, Illinois + 11 more
Completed Phase 4 Interventional Results available

Drug and Non-Drug Treatment Of Severe Migraine

NCT00910689
Conditions
Migraine Headache
Interventions
Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
Drug · Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 65 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Athens, Ohio • Westerville, Ohio
Conditions
Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions
Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%
Drug
Lead sponsor
Waihong Chung
Other
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island